Vetoquinol: 2019 Sales: €396.0 Million (up 7.6%)
23 Gennaio 2020 - 05:45PM
Business Wire
Regulatory News:
The Vetoquinol Group (Paris:VETO) posted 2019 sales of €396.0
million, up 7.6% as reported and up 6.1% at constant exchange
rates.
Sales of Essentials products, the driving force behind
Vetoquinol’s strategy, totaled €190.6 million, up 5.1% at constant
exchange rates. Essentials products accounted for 48.1% of
Group sales in 2019.
KEY FIGURES
Q4 2019 Group Sales €112.0 million up
10.6% at constant exchange rate
Q4 2019 Essentials Sales €53.6 million up
7.2% at constant exchange rate
Sales of companion animal products (€226.3 million) accounted
for 57.1% of total Vetoquinol sales, up 8.4% at constant exchange
rates and up 10.4% as reported. Sales of livestock products came to
€169.7 million, up 3.2% at constant exchange rates; sales generated
by recently acquired Clarion (Brazil) offset the decline in sales
of reproduction range.
All Vetoquinol strategic territories posted growth in 2019, with
the Americas up 11.3%, Europe up 3.8% and Asia Pacific up 2.0% at
constant exchange rates. Growth in the Americas was boosted by
Clarion sales in Brazil from April 2019.
Fourth quarter sales amounted to €112.0 million, up 12.2% as
reported and up 10.6% at constant exchange rates. Recent
acquisitions boosted fourth quarter sales by 4.0% and exchange rate
fluctuations also had a 1.6% positive impact.
All strategic territories posted strong fourth quarter growth at
constant exchange rates, with Europe up 3.0%, the Americas up 21.6%
and Asia Pacific up 7.1%. Fourth quarter sales of Essentials
products rose 7.2% at constant exchange rates.
As of December 31, 2019, the financial structure of Vetoquinol
remains solid. The year-end results will take into account the
impact of the industrial steps initiated during the second
semester. The audit of the Group financial statements was in
progress at time of release.
Vetoquinol CEO Matthieu Frechin said: “We achieved a solid
second semester and our annual performance is the result of our
focused strategy and the acquisition in Brazil. This is reflected
in the continued growth in Essentials sales across all strategic
territories. The integration of Clarion in Brazil is progressing
according to plan, while we continue to work on reorganizing our
production facilities in Europe. We therefore look forward to 2020
with confidence in our plans to invest and secure sustainable
long-term growth for our Group.”
€m
2019
2018
Change (reported data)
Change at constant exchange
rates
Change (like-for- like)
Q1 Sales
90.9
87.6
+3.7%
+2.3%
+2.3%
Q2 Sales
92.9
90.3
+2.9%
+1.3%
-1.4%
Q3 Sales
100.2
90.2
+11.0%
+9.4%
+5.3%
Q4 Sales
112.0
99.8
+12.2%
+10.6%
+6.6%
Aggregate 12-months Sales
396.0
367.9
+7.6%
+6.1%
+3.3%
Next update: 2019 Annual results – March 26, 2020 before
market open.
About Vetoquinol Vetoquinol is a leading global animal
health company that supplies drugs and non-medicinal products for
the livestock (cattle and pigs) and pet (dogs and cats) markets. As
an independent pure player, Vetoquinol designs, develops and sells
veterinary drugs and non-medicinal products in Europe, the Americas
and the Asia Pacific region. Since its foundation in 1933,
Vetoquinol has pursued a strategy combining innovation with
geographical diversification. The Group's hybrid growth is driven
by the reinforcement of its product portfolio coupled with
acquisitions in high potential growth markets. At December 31, 2019
Vetoquinol employs 2,372 people. Vetoquinol has been listed on
Euronext Paris since 2006 (symbol: VETO).
For further information, go to: www.vetoquinol.com.
ALTERNATIVE PERFORMANCE INDICATORS
Vetoquinol Group management considers that these indicators,
which are not defined by IFRS, provide additional information that
is relevant for shareholders seeking to analyze underlying trends
and Group performance and financial position. They are used by
management for performance analysis.
Essentials products: The products referred to as
“Essentials” comprise veterinary drugs and non-medical products
sold by the Vetoquinol Group. They are existing or potential
market-leading products designed to meet the daily requirements of
vets in the companion animal or livestock sector. They are intended
for sale worldwide and their scale effect improves their economic
performance.
Constant exchange rates: Application of the previous
period’s exchange rates to the current financial year, all other
things remaining equal.
Like-for-like growth: Year-on-year sales growth in terms
of volume and/or price at constant exchange rates.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200123005477/en/
VETOQUINOL Investor
Relations Fanny TOILLON Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com
KEIMA Communication Investor and
Media Relations Emmanuel DOVERGNE Tel.: +33 (0)1 56 43 44 63
emmanuel.dovergne@keima.fr
Grafico Azioni Vetoquinol (EU:VETO)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Vetoquinol (EU:VETO)
Storico
Da Mar 2023 a Mar 2024